Skip to search formSkip to main contentSkip to account menu

otamixaban

Known as: 2-(3-carbamimidoylbenzyl)-3-(4-(1-oxypyridin-4-yl)benzoylamino)butyric acid methyl ester, 2-(R)-(3-carbamimidoylbenzyl)-3-(R)-(4-(1-oxypyridin-4-yl)benzoylamino)butyric acid methyl ester 
An orally active inhibitor of coagulation factor Xa (activated factor X) with anticoagulant activity. Otamixaban has a short half-life of 1.5 to 3… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Cyclic N-OxidesFactor Xa inhibitorsPyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Prognostic performance of a high-sensitivity cardiac troponin I assay in patients with non-ST-elevation acute coronary syndrome.
BACKGROUND High-sensitivity assays for cardiac troponin enable more precise measurement of very low concentrations and improved… 
Review
2010
Review
2010
Clinical Pharmacology of Direct and Indirect Factor Xa Inhibitors
The limitations of conventional anticoagulants have stimulated the development of new anticoagulants. The central position of… 
Highly Cited
2009
Highly Cited
2009
Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial
2009
2009
Resumen de los ensayos clínicos presentados en las sesiones científicas del Congreso de la Sociedad Europea de Cardiología (Barcelona, España, 29 de agosto-2 de septiembre de 2009)
Highly Cited
2007
Highly Cited
2007
Randomized, Double-Blind, Dose-Ranging Study of Otamixaban, a Novel, Parenteral, Short-Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention: The SEPIA-PCI Trial
Background— The optimal anticoagulant regimen for percutaneous coronary intervention (PCI) remains to be determined. Otamixaban… 
Review
2007
Review
2007
The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development.
Factor Xa (fXa) is a critical serine protease situated at the confluence of the intrinsic and extrinsic pathways of the blood… 
2006
2006
Pharmacokinetics of Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Male Subjects: Pharmacokinetic Model Development for Phase 2/3 Simulation of Exposure
The pharmacokinetics of otamixaban was investigated in healthy male subjects over a wide range of intravenous doses, with… 
2006
2006
Asymmetric synthesis of intermediates for otamixaban and premafloxacin by the chiral ligand-controlled asymmetric conjugate addition of a lithium amide.
A chiral ligand-controlled conjugate addition reaction of lithium benzyl(trimethylsilyl)amide with tert-butyl enoates gave the… 
2005
2005
Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor
Summary This manuscript reports the assessment of pharmacodynamic (PD) markers of anti-coagulation in the first-in-man study with… 
2004
2004
Diastereoselective alkylation of beta-amino esters: structural and rate studies reveal alkylations of hexameric lithium enolates.
Alkylation of beta-amino ester enolates proceeds with high diastereoselectivity. Single crystal, powder, and solution X-ray… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)